

Special Issue

Toxicities of Antineoplastic Therapies

Message from the Guest Editors

The rapid development of antineoplastic therapies, has transformed cancer treatment and improved survival across a wide range of malignancies. These advances have shifted many cancers toward chronic disease management, offering prolonged control and durable responses. However, this progress has been accompanied by an expanding spectrum of toxicities that can affect virtually every organ system. Such adverse effects may limit therapeutic efficacy, impair quality of life, and, in severe cases, necessitate treatment interruption or discontinuation.

Identification of predictive biomarkers, refinement of monitoring strategies, and development of effective supportive care strategies to mitigate both acute and long-term complications of antineoplastic therapies continue to rise as key priorities in advancing modern cancer care. Continued high-quality research into the biological mechanisms underlying these toxicities and their clinical manifestations is essential to optimize therapeutic benefit, minimize harm, and ensure that advances in cancer therapy translate into meaningful improvements in patient outcomes.

Guest Editors

Dr. Ysabella Van Sebille

Dr. Hannah Wardill

Dr. Connor Williams

Deadline for manuscript submissions

25 December 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/260454

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)